Status:
UNKNOWN
Evaluation of Efficacy of Lycium Barbarum Polysaccharide in People With Subthreshold Depression
Lead Sponsor:
Guangzhou Psychiatric Hospital
Collaborating Sponsors:
Fifth Affiliated Hospital of Guangzhou Medical University
Conditions:
Subthreshold Depression
Depressive Symptoms
Eligibility:
All Genders
12-18 years
Phase:
NA
Brief Summary
Lycium barbarum, a traditional Chinese herbal medicine, is a commonly used herb in the traditional Chinese pharmacopoeia . Its main active ingredient, lycium barbarum polysaccharide (LBP), is reported...
Eligibility Criteria
Inclusion
- 15-25 scores in the Beck Depression Rating Scale (BDI- II)
- There is no contraindication of taking LBP.
Exclusion
- Current treatment for a mental health problem from a mental health professional
- Current and lifetime history of psychiatric disorders (e.g major depressive disorder, as ascertained by CIDI
- Systemic disease requiring regular medication.
- There are suicidal ideation, suicidal attempt, suicide behavior and attempted suicide.
- Dislike of or allergy to goji berry
- Hormone or Endocrine therapeutic drugs are being taken.
- Long-term use of lycium chinensis in recent three months
Key Trial Info
Start Date :
May 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2021
Estimated Enrollment :
172 Patients enrolled
Trial Details
Trial ID
NCT04032795
Start Date
May 15 2019
End Date
December 30 2021
Last Update
November 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Affiliated Fifth Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China